Anti-GPC-3 chimeric antigen receptor (CAR) T-cells, combined with soluble IL-15, have shown significant efficacy in preclinical mouse models of hepatocellular carcinoma (HCC), highlighting GPC-3’s therapeutic potential. Here, IL15 is linked to hepatocellular carcinoma.